BioCentury
ARTICLE | Clinical News

Neuraceq regulatory update

March 24, 2014 7:00 AM UTC

FDA approved Neuraceq [18F]-florbetaben from Piramal for PET imaging of the brain to estimate beta amyloid neuritic plaque density in adults with cognitive impairment who are being evaluated for Alzheimer's disease (AD) and other causes of cognitive decline. The European Commission approved the product as NeuraCeq last month. The company plans to launch the product in the U.S. and Europe in 2Q14 and 3Q14. Piramal declined to disclose pricing details. ...